上皮性卵巢癌组织中matriptase表达及临床意义

Expression and prognosis of matriptase in epithelial ovarian cancer

目的探讨丝氨酸蛋白酶(matriptase)在上皮性卵巢癌组织中的表达及临床意义。方法上皮性卵巢癌患者65例为卵巢癌组,良性卵巢肿瘤患者20例为良性肿瘤组,卵巢切除术后组织病理示无病变的患者20例为对照组,采用免疫组织化学法检测3组卵巢组织matriptase蛋白阳性表达率,分析卵巢癌组卵巢组织matriptase蛋白阳性表达率与临床病理特征的关系,采用Kaplan-Meier生存曲线法分析matriptase蛋白阳性表达与上皮性卵巢癌患者预后的关系。结果卵巢癌组卵巢组织matriptase蛋白阳性表达率(78.5%)明显高于良性肿瘤组(45.0%)和对照组(15.0%)(P<0.05),良性肿瘤组与对照组比较差异无统计学意义(P>0.05);卵巢癌组FIGOⅢ～Ⅳ期患者卵巢组织matriptase蛋白阳性表达率(92.7%)高于Ⅰ～Ⅱ期患者(54.2%)(P<0.05),G_3级患者卵巢组织matriptase蛋白阳性表达率(94.4%)高于G_1～G_2级患者(58.6%)(P<0.05),淋巴结转移患者卵巢组织matriptase蛋白阳性表达率(94.4%)高于无淋巴结转移患者(58.6%)(P<0.05);卵巢癌组matriptase阳性表达者5 a生存率(45.5%)明显低于阴性表达者(78.6%)(P<0.05)。结论 matriptase阳性表达可能在卵巢癌发生、发展和浸润、转移中起重要作用,检测matriptase蛋白表达有可能判断上皮性卵巢癌的恶性程度,matriptase有可能作为判断肿瘤晚期和侵袭性行为的生物标志物。

Objective To investigate the expression and clinical significance of matriptase in epithelial ovarian cancer(EOC). Methods The positive rates of matriptase protein were detected by immunohistochemical method in 65 patients with EOC(EOC group), 20 patients with benign tumors(benign group) and 20 patients with histopathologically confirmed normal ovarian tissues after ovariotomy(control group). The correlation of the positive rates of matriptase protein with clinicopathologic features was analyzed. Kaplan-Meier method was used to analyze the relationship between the positive rate of matriptase protein and the prognosis of the patients with EOC. Results The positive rate of matriptase protein was significantly higher in ECO group(78.5%) than that in benign group(45.0%) and control group(15.0%)(P<0.05), and showed no significant difference between benign group and control group(P>0.05). The positive rate of matriptase protein was significantly higher in ovarian tissues with FIGO stage Ⅲ-Ⅳ(92.7%) than that in stage Ⅰ-Ⅱ in ECO group(54.2%)(P<0.05), in ovarian tissues with grade G_3(94.4%) than that in with grade G_1 and G_2(58.6%)(P<0.05), and in patients with lymph node metastasis(94.4%) than that in patients without lymph node metastasis(58.6%)(P<0.05). The 5-year survival rate was significantly lower in patients with positive matriptase expression(45.5%) than that in patients with negative matriptase expression(78.6%) in EOC group(P<0.05). Conclusion The positive expression of matriptase might be involved in the development, progression, infiltration and metastasis of EOC. The detection of matriptase protein is expected to be used to assess the malignant degree of EOC, and matriptase might be a biomarker for judging advanced stage and invasion of EOC.